CTRI/2022/09/045732已完成2 期
Clinical study to evaluate the efficacy and safety of Sandalwood Rose Age Defying Eye Butter in healthy human subjects
Transformative Learning Solutions Pvt Ltd0 个研究点目标入组 32 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Female adult subjects in general good health as determined from a recent medical history.
- •2.Subjects in the age group of 30-55 years (both ages inclusive).
- •3.Subjects having periorbital Melanosis/ under eye dark- circle on grade 2 or more as per MSCR photo numerical scale (Refer Appendix-2)
- •4.Subject having eye puffiness in under eye area on grade 2 or more as per MSCR photo numerical scale (Refer Appendix-2)
- •5.Subject should be willing to abstain from other under eye treatment during the study period.
- •6.Subjects willing to give a voluntary written informed consent and agree to come for regular follow up.
- •7.Subject agreeable for photography.
- •8.Subjects willing to abide by and comply with the study protocol.
- •9.Subjects who have not participated in a similar investigation in the past two weeks.
- •10.Subjects who are willing not to participate in any other clinical study during participation in the current study
排除标准
- •1.A known history or present condition of allergic response to any cosmetic products.
- •2.Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.
- •3.Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy.
- •4.Subjects having eye infection or allergy as per medical history.
- •5.Subjects having extremely sensitive eye condition.
- •6.Subjects having eye disorders like cataract, conjunctivitis, etc. as per medical history
- •7.Subjects who are pregnant, lactating or nursing.
- •8.Intense sun exposure/ photo allergen city/toxicity.
- •9.Chronic illness which may influence the cutaneous state.
- •10.Subject participating in any other cosmetic or therapeutic trial.
- •11.Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness.
研究者
相似试验
未知
3 期
Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasisPsoriasisJPRN-jRCT2080220313Mitsubishi Tanabe Pharma Corporation
已完成
3 期
result of vitimelin tablet and vitimelin oil in vitiligoCTRI/2021/04/033014DrVasishths Ayuremedies30
进行中(未招募)
不适用
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AEUCTR2005-003552-35-DEOctapharma AG116
已完成
2 期
Clinical study on Dabur gel in reduction of oral malodor.CTRI/2021/07/034750Dabur India limited161
进行中(未招募)
不适用
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AIdiopathic thrombocytopenic purpura, in adults actively bleeding or at high risk bleeding.MedDRA version: 7.0Level: LLTClassification code 10021245EUCTR2005-003552-35-ATOctapharma AG116
